The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Browse by Topic

  1. Acute Respiratory Infections (195)
  2. Airways (507)
    1. Allergic rhinitis (1)
    2. Alpha 1 - antitrypsin deficiency (1)
    3. Aspergillosis, allergic bronchopulmonary (2)
    4. Asthma, acute - non-pharmacotherapy (3)
    5. Asthma, acute - pharmacotherapy (39)
    6. Asthma, chronic - non-pharmacotherapy (77)
    7. Asthma, chronic - pharmacotherapy (156)
      1. Adverse effects of treatment (6)
      2. Allergen immunotherapy (2)
      3. Antibiotics (1)
      4. Antibodies, monoclonal (2)
      5. Anticholinergics (3)
      6. Antihistamines (1)
      7. Anti-inflammatory agents, non-steroidal (1)
      8. Beta-agonists, long-acting (25)
        1. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and childrenReview
        2. Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and childrenReview
        3. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthmaReview
        4. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in childrenReview
        5. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthmaReview
        6. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and childrenReview
        7. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and childrenReview
        8. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and childrenReview
        9. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and childrenReview
        10. Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthmaReview
        11. Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and childrenReview
        12. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidReview
        13. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthmaReview
        14. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse eventsReview
        15. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse eventsReview
        16. Regular treatment with formoterol for chronic asthma: serious adverse eventsReview
        17. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse eventsReview
        18. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthmaReview
        19. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse eventsReview
        20. Regular treatment with salmeterol for chronic asthma: serious adverse eventsReview
        21. Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviewsReviewOverview
        22. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviewsReviewOverview
        23. Stopping long-acting beta2-agonists (LABA) for adults with asthma well-controlled on LABA and inhaled corticosteroidsProtocol
        24. Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroidsProtocol
        25. Vilanterol and fluticasone for asthmaProtocol
      9. Beta-agonists, short-acting (8)
      10. Cardioselective beta-blockers (1)
      11. Combination and additive therapies (21)
      12. Cromones (5)
      13. Gastro-oesophogeal reflux treatment (1)
      14. Histamine antagonists (1)
      15. Inhaler devices and delivery of therapy (2)
      16. Leukotriene antagonists (6)
      17. Management in pregnancy (1)
      18. Muscarinic antagonists (3)
      19. Other (1)
      20. Phosphodiesterases (0)
      21. Steroids, inhaled (47)
      22. Steroids, intranasal (1)
      23. Steroids, oral (3)
      24. Steroid sparing agents (10)
      25. Vaccines (2)
      26. Xanthines (2)
    8. Asthma, occupational (1)
    9. Asthma, primary prevention (0)
    10. Breathing dysregulation/hyperventilation syndrome (2)
    11. Bronchiectasis (24)
    12. Bronchoconstriction, exercise-induced (7)
    13. Chronic obstructive pulmonary disease, exacerbations (17)
    14. Chronic obstructive pulmonary disease, stable - non-pharmacotherapy (38)
    15. Chronic obstructive pulmonary disease, stable - pharmacotherapy (73)
    16. Cough, chronic (16)
    17. Cough, post-viral (1)
    18. Cough, subacute (2)
    19. Diagnostic test accuracy (1)
    20. Global developmental delay (1)
    21. Hypertension, pulmonary (7)
    22. Idiopathic pulmonary fibrosis (2)
    23. Lung disease, aspiration (1)
    24. Lung diseases, interstitial (5)
    25. Pleural diseases (1)
    26. Sarcoidosis, pulmonary (2)
    27. Sleep apnoea, obstructive (18)
    28. Stridor, post-extubation (1)
    29. Tracheomalacia (1)
    30. Wheeze (7)
  3. Anaesthesia (343)
  4. Back (314)
  5. Bone, Joint and Muscle Trauma (281)
  6. Breast Cancer (97)
  7. Childhood Cancer (53)
  8. Colorectal Cancer (276)
  9. Consumers and Communication (102)
  10. Cystic Fibrosis and Genetic Disorders (175)
  11. Dementia and Cognitive Improvement (282)
  12. Depression, Anxiety and Neurosis (807)
  13. Developmental, Psychosocial and Learning Problems (189)
  14. Drugs and Alcohol (102)
  15. Ear, Nose and Throat Disorders (146)
  16. Editorial Unit (13216)
  17. Effective Practice and Organisation of Care (151)
  18. Epilepsy (103)
  19. Eyes and Vision (212)
  20. Fertility Regulation (106)
  21. Gynaecological Cancer (195)
  22. Haematological Malignancies (143)
  23. Heart (215)
  24. Hepato-Biliary (400)
  25. HIV/AIDS (161)
  26. Hypertension (130)
  27. Incontinence (163)
  28. Infectious Diseases (166)
  29. Inflammatory Bowel Disease and Functional Bowel Disorders (125)
  30. Injuries (235)
  31. Lung Cancer (43)
  32. Menstrual Disorders and Subfertility (268)
  33. Metabolic and Endocrine Disorders (151)
  34. Methodology Review (41)
  35. Movement Disorders (95)
  36. Multiple Sclerosis and Rare Diseases of the Central Nervous System (62)
  37. Musculoskeletal (362)
  38. Neonatal (397)
  39. Neuromuscular Disease (268)
  40. Occupational Safety and Health (131)
  41. Oral Health (225)
  42. Pain, Palliative and Supportive Care (322)
  43. Peripheral Vascular Diseases (442)
  44. Pregnancy and Childbirth (695)
  45. Prostatic Diseases and Urologic Cancers (59)
  46. Public Health (42)
  47. Renal (252)
  48. Schizophrenia (288)
  49. Sexually Transmitted Infections (21)
  50. Skin (301)
  51. Stroke (231)
  52. Tobacco Addiction (92)
  53. Upper Gastrointestinal and Pancreatic Diseases (239)
  54. Wounds (220)

SEARCH